




The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 4.9% points. The greatest weakness of Viracta Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 105% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	40,492
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,972
Liabilities, Non-Current	0
Other Assets	10
Other Compr. Net Income	-41
Other Expenses	2,917
Other Liabilities	0
Other Net Income	92
Other Revenues	7,956
Property and Equipment	23
Research and Development	28,891
Selling, General and Administrative Expense	10,838

Output Variable	Value in 1000 USD
Assets	40,525
Liabilities	33,972
Expenses	42,646
Revenues	7,956
Stockholders Equity	6,553
Net Income	-34,598
Comprehensive Net Income	-34,618
BaseVar	62,616
ECR before Limited Liability	-55%
Economic Capital Ratio	138%